Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with BRCA1/2 Pathogenic Variants: A Population-Based Retrospective Cohort Study
Current Oncology · 2023
DOI: 10.3390/curroncol30100678 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, 2023. Verfasst von Aimee Roebothan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Memorial University, St. John's, NL 1AB 3V6, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NL SUPPORT Patient-Oriented Research.
Abstract (Originalsprache)
Pathogenic variants (PVs) in BRCA1 and BRCA2 increase the lifetime risks of breast and ovarian cancer. Guidelines recommend breast screening (magnetic resonance imaging (MRI) and mammogram) or risk-reducing mastectomy (RRM) and salpingo-oophorectomy (RRSO). We sought to (1) characterize the population of BRCA1/2 PV carriers in Newfoundland and Labrador (NL), (2) evaluate risk-reducing interventions, and (3) identify factors influencing screening and prevention adherence. We conducted a retrospective study from a population-based provincial cohort of BRCA1/2 PV carriers. The eligibility criteria for risk-reducing interventions were defined for each case and patients were categorized based on their level of adherence with recommendations. Chi-squared and regression analyses were used to determine which factors influenced uptake and level of adherence. A total of 276 BRCA1/2 PV carriers were identified; 156 living NL biological females composed the study population. Unaffected females were younger at testing than those with a cancer diagnosis (44.4 years versus 51.7 years; p = 0.002). Categorized by eligibility, 61.0%, 61.6%, 39.0%, and 75.7% of patients underwent MRI, mammogram, RRM, and RRSO, respectively. Individuals with breast cancer were more likely to have RRM (64.7% versus 35.3%; p < 0.001), and those who attended a specialty hereditary cancer clinic were more likely to be adherent to recommendations (73.2% versus 13.4%; p < 0.001) and to undergo RRSO (84.1% versus 15.9%; p < 0.001). Nearly 40% of the female BRCA1/2 PV carriers were not receiving breast surveillance according to evidence-based recommendations. Cancer risk reduction and uptake of breast imaging and prophylactic surgeries are significantly higher in patients who receive dedicated specialty care. Organized hereditary cancer prevention programs will be a valuable component of Canadian healthcare systems and have the potential to reduce the burden of disease countrywide.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Memorial University, St. John's, NL 1AB 3V6, Canada.
- Centre for Translational Genomics, NL Health Services, St. John's, NL 1AB 3V6, Canada.
- Discipline of Laboratory Medicine, Faculty of Medicine, Memorial University, St. John's, NL 1AB 3V6, Canada.
- Discipline of Oncology, Faculty of Medicine, Memorial University, St. John's, NL 1AB 3V6, Canada.
- Community Health and Humanities, Faculty of Medicine, Memorial University, St. John's, NL 1AB 3V6, Canada.
- Division of Gynecologic Oncology, Faculty of Medicine, Memorial University, St. John's, NL 1AB 3V6, Canada.
ORCID-Profile: Kerri N Smith, Holly Etchegary, Lesa Dawson
Förderung
- NL SUPPORT Patient-Oriented Research
Zitieren
APA
Roebothan, A., Smith, K. N., Seal, M., Etchegary, H., & Dawson, L. (2023). Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with BRCA1/2 Pathogenic Variants: A Population-Based Retrospective Cohort Study. Current Oncology. https://doi.org/10.3390/curroncol30100678
Vancouver
Roebothan A, Smith KN, Seal M, Etchegary H, Dawson L. Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with BRCA1/2 Pathogenic Variants: A Population-Based Retrospective Cohort Study. Current Oncology. 2023. doi:10.3390/curroncol30100678
BibTeX
@article{Roebothan2023,
author = {Roebothan, Aimee and Smith, Kerri N and Seal, Melanie and Etchegary, Holly and Dawson, Lesa},
title = {Specialty Care and Counselling about Hereditary Cancer Risk Improves Adherence to Cancer Screening and Prevention in Newfoundland and Labrador Patients with BRCA1/2 Pathogenic Variants: A Population-Based Retrospective Cohort Study},
journal = {Current Oncology},
year = {2023},
doi = {10.3390/curroncol30100678}
}
EUVIMED